Pharmaceutical industry
The total control of drug development by pharmaceutical companies is both problematic and unsustainable. Pharmaceutical companies are often more concerned about profits than public health priorities or corporate accountability. As a result, key health priorities are neglected and people lack access to the medicine they need. Companies engage in harmful and unethical research practices, and irresponsible marketing practices. SOMO researches the policies and practices around pharmaceutical drug development, with a particular focus on the ethics of drug testing in low and middle income countries. Clinical trials in these countries often involve vulnerable people, raising serious ethical questions. We push pharmaceutical companies to act with due diligence in line with the UN Guiding Principles on Business and Human Rights in relation to peoples’ participation in clinical trials, as well as Post-Trial Access (PTA) to medicine.
Overview of articles
-
New research reveals large-scale tax avoidance by coronavirus test manufacturer QiagenPosted in category:NewsPublished on: -
Profiting from a pandemic Published on:
Vincent KiezebrinkPosted in category:Publication
Vincent Kiezebrink -
-
Proposals for achieving equitable global access for treatments, vaccines and diagnosticsPosted in category:Published on:Statement
-
-
The earnings model of the pharmaceutical industry needs to be overhauledPublished on:Posted in category:Opinion
-
We Can’t Afford Big Pharma’s GreedPosted in category:Opinion
Rodrigo FernandezPublished on:
Rodrigo Fernandez -
Private gains we can ill afford Published on:
Rodrigo FernandezPosted in category:Publication
Rodrigo Fernandez
-
SOMO reveals the financialisation of the pharmaceutical industry and the potentially deadly costsPosted in category:NewsPublished on: -
-
-
Make future corona medicine affordable and accessible for everyonePosted in category:Published on:Statement
-
-
-
-
